NECVAX NEO1
Alternative Names: NECVAX-NEO1Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator NEC Corporation; VAXIMM
- Developer NEC Bio Therapeutics; NEC Corporation; NEC OncoImmunity
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours; Triple negative breast cancer
Most Recent Events
- 14 Oct 2024 NEC Bio Therapeutics plans a phase I/II trial for Solid tumour (Combination therapy) in October 2024 (PO) (NCT06631079)
- 08 Oct 2024 Phase-I/II clinical trials in Triple-negative-breast-cancer (Neoadjuvant therapy, First-line therapy) in Germany (PO) (NCT06631092)
- 07 Oct 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy) in Spain (PO) (NCT06631079)